A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual care, diet and exercise, and weight loss surgeries.
This article was originally published on MedicalXpress.com
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
© 2025 SimplyWell.ca